奈达铂致非小细胞肺癌患者贫血的临床分析

Analysis of clinical factors on nedaplatin-induced anemia in patients with non-small cell lung cancer

目的分析奈达铂化疗后非小细胞肺癌(NSCLC)患者发生贫血的临床影响因素,为奈达铂安全用药提供理论依据。方法选取徐州医科大学附属医院应用奈达铂化疗的NSCLC患者124例,统计分析化疗后不同年龄、性别、病理分型、分期患者的贫血发生率。结果124例患者的贫血发生率为70.16%,其中年龄>65岁的患者的贫血发生率明显高于年龄≤65岁的患者(84.85% vs. 64.84%,P<0.05),鳞癌患者的贫血发生率明显高于腺癌患者(76.47% vs. 53. 85%,P <0.05),吸烟患者的贫血发生率明显高于不吸烟患者(76. 19% vs. 57.50%,P<0.05)。结论 NSCLC患者接受奈达铂化疗后,老年、鳞癌和吸烟患者贫血发生率高,用药前应注意预防贫血。

Objective To analyze the clinical influencing factors of anemia in patients with non - small cell lung cancer ( NSCLC) after nedaplatin chemotherapy, and to provide theoretical basis for the safe use of nedaplatin. Methods A total of 124 NSCLC patients who received nedaplatin chemotherapy in the Affiliated Hospital of Xuzhou Medical Uni versity were selected. The incidence of anemia in patients with different age, sex, pathological type and stage after chem otherapy was analyzed. Results The incidence of anemia in 124 patients was 70. 16%. The incidence of anemia in pa tients >65 years was significantly higher than that in patients ≤65 years (84. 85% vs. 64. 84%, P < 0.05 ). The inci dence of anemia in squamous cell carcinoma patients was significantly higher than that in adenocarcinoma patients (76.47% vs. 53. 85%, P < 0. 05 ). The incidence of anemia in smokers was significantly higher than that in non - smokers (76. 19% vs. 57.50%, P <0.05). Conclusions The incidence of anemia in elderly, squamous cell carcino ma and smoking patients is high after receiving nedaplatin chemotherapy in NSCLC patients. Anemia should be prevented before taking nedaplatin regimen.